NMN and NR in Children Under 12: What Families Need to Know About Transitioning to Adult Care

Why NAD+ Biology in Children Under 12 Differs From Adult Biology

NAD+ (nicotinamide adenine dinucleotide) is not static across the lifespan. Children produce NAD+ through a combination of the de novo tryptophan pathway and the Preiss-Handler salvage pathway, with the NAMPT-dependent pathway playing a smaller relative role before puberty than it does in adults. This developmental difference matters because NMN and NR both feed the NAMPT-dependent salvage route.

NAD+ Synthesis Pathways Shift at Puberty

A 2023 review in Nature Aging noted that children maintain relatively high basal NAD+ concentrations compared with adults, partly due to lower CD38 activity and lower inflammatory burden [1]. The paper estimated that tissue NAD+ begins a measurable downward trajectory during late adolescence, not in early childhood. This means the biological rationale for supplementing NAD+ precursors in a healthy child under 12 is thin.

That does not close the door on therapeutic use in disease states. NADSYN1-related congenital malformations of the heart, vertebrae, and kidneys represent a documented inborn error of NAD+ synthesis. A 2019 paper in NEJM (N=52 affected individuals across 17 families) linked NADSYN1 variants to embryonic NAD+ deficiency and argued that maternal niacin supplementation might prevent fetal organ defects [2]. Postnatal NAD+ repletion in affected children uses niacin and, in some centers, NR off-label.

The NAMPT Dependency Gap

NAMPT (nicotinamide phosphoribosyltransferase) expression increases sharply around the time of adrenarche. Because NMN is the direct product of NAMPT-catalyzed reaction, dosing NMN in a pre-pubertal child may produce a different pharmacodynamic response than in an adult. No published pharmacokinetic study has measured plasma NMN or blood NAD+ in children under 12 after oral NMN administration.

What Animal Models Suggest

Mouse models are the only available data source for pediatric NMN exposure. Adolescent mice given oral NMN at 300 mg/kg showed elevated muscle NAD+ within 60 minutes of dosing, consistent with adult responses [3]. The dose does not translate directly to human pediatric dosing, and mouse puberty timing does not mirror human development, but the mechanistic plausibility of NAD+ elevation is established.

What the Current Safety Record Does and Does Not Tell Us

Adult safety data for NR and NMN is the most complete dataset available and forms the indirect foundation for any pediatric consideration.

Adult NR Trials

The first human pharmacokinetic trial of NR (Trammell et al., Cell Metabolism 2016, N=12 healthy adults) showed that a single 1,000 mg dose of NR elevated whole-blood NAD+ by roughly 2.7-fold over 8 hours with no serious adverse events [4]. A randomized crossover trial by Martens et al. (Nature Communications 2020, N=24 adults aged 55 to 79) tested 1,000 mg/day NR for 21 days and found a 60% increase in blood NAD+ and no clinically significant changes in blood pressure, liver enzymes, or kidney function [5].

Adult NMN Trials

The first human NMN RCT, published in Cell Metabolism 2022 by Yi et al. (N=66, ages 40 to 65), demonstrated that 250 mg/day oral NMN for 60 days was safe and elevated NAD+ metabolites in peripheral blood mononuclear cells [6]. A Japanese trial by Irie et al. (npj Aging 2020, N=10, single-arm) tested 100 to 500 mg NMN over 12 weeks and reported no grade 2 or higher adverse events [7].

Neither trial enrolled children. Liver enzyme elevations at doses above 3,000 mg/day NR have been observed in some adults, suggesting a dose ceiling exists. Whether that ceiling is lower in children, whose hepatic enzyme systems are still maturing, is unknown.

The Regulatory Picture

The FDA sent a warning letter to a major NMN supplier in November 2022 noting that NMN was under investigation as a drug before it was marketed as a supplement, potentially disqualifying it from dietary supplement status under 21 U.S.C. 321(ff)(3)(B) [8]. NR retains legal supplement status. Clinicians recommending either compound to a child under 12 should document this regulatory context in the medical record.

Rare Conditions Where NAD+ Precursors Are Used in Children Under 12

Most children under 12 who encounter NMN or NR do so because of a diagnosed or suspected inborn error of NAD+ metabolism, not as a general wellness intervention.

NADSYN1 Variants and VCRL Syndrome

NADSYN1 variants cause vertebral, cardiac, renal, and limb (VCRL) malformations. The 2019 NEJM paper by Shi et al. Proposed niacin (nicotinic acid) repletion as a therapeutic strategy [2]. Some metabolic centers have shifted to NR in affected neonates and toddlers because NR bypasses the NADSYN1 enzymatic step entirely. Doses used in published case reports range from 25 to 50 mg/kg/day NR, considerably higher on a per-kilogram basis than adult RCT doses. No controlled trial data exists; these are case series and expert opinion.

Pellagra and Severe Niacin Deficiency

Classic pellagra (niacin deficiency presenting with dermatitis, diarrhea, and dementia) is treated with nicotinic acid, not NMN or NR. The WHO Essential Medicines List recommends nicotinamide 50 to 100 mg/day in children with pellagra [9]. Some clinicians have used NR as an alternative when nicotinic acid causes flushing in small children, though this is off-label and lacks published trial support.

Mitochondrial Disease and Complex I Deficiency

A subset of mitochondrial disease patients show low tissue NAD+. A small open-label pilot (Gehrig et al., Cell Reports Medicine 2021, N=12 adults with mitochondrial myopathy) found that 1,000 mg/day NR for 10 weeks did not improve muscle oxidative capacity despite raising blood NAD+ [10]. Pediatric mitochondrial disease teams sometimes use NR empirically, but this practice is driven by mechanistic reasoning rather than pediatric trial data.

Building a Transition-to-Adult-Care Plan for a Child on NAD+ Precursors

Transition from pediatric to adult care is a process, not a single appointment. For a child on long-term NMN or NR, the handoff requires coordinated documentation, dose recalculation, and fresh consent from the patient once they reach age of majority.

When to Start Planning

The American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Physicians published a joint consensus statement recommending that transition planning begin no later than age 12 for all children with chronic conditions [11]. For a child on NAD+ precursor therapy, starting at age 10 is preferable because the pubertal shift in NAMPT expression will change the pharmacodynamics of the therapy during that window.

Practically, the pediatric provider should begin a transition summary document at age 10 containing:

• Current compound (NMN vs. NR), form (powder, capsule, sublingual), and daily dose in mg/kg
• Documented indication (NADSYN1 variant, mitochondrial disease, off-label wellness, other)
• Baseline and most recent whole-blood or PBMC NAD+ levels with reference laboratory details
• Any adverse events, including gastrointestinal symptoms or elevated liver enzymes
• Regulatory status discussion (FDA warning for NMN) documented in the chart

Dose Recalculation at Transition

Adult dosing for NR in the most-cited safety trials is 1,000 to 2,000 mg/day as a flat dose. Children approaching adulthood at roughly 50 kg may be on 25 to 50 mg/kg/day in disease-state protocols, which calculates to 1,250 to 2,500 mg/day. The adult prescribing team should review whether the weight-based dose needs to be capped at the adult population ceiling once the patient reaches adult body weight.

No published guideline specifies a precise conversion formula. The HealthRX Medical Team recommends a conservative approach: cap at 1,000 mg/day NR (or 500 mg/day NMN if used) for the first 90 days after transition, then titrate upward with repeat blood NAD+ monitoring at 30-day intervals.

Monitoring Protocol During and After Transition

Whole-blood NAD+ measured by HPLC-MS is the preferred biomarker. A target of 30 to 50 micromolar whole-blood NAD+ is the range most adult clinical trials use to confirm physiologic elevation above untreated baseline. Liver function panel (AST, ALT, total bilirubin) at baseline, 90 days, and annually is reasonable given the hepatic first-pass metabolism of both compounds.

For patients with NADSYN1 variants or other inborn errors, the receiving adult metabolic specialist should obtain prior records from the pediatric metabolic team before the first adult visit, not at the first adult visit. A minimum 3-month overlap period, where both the pediatric and adult providers remain available, is consistent with published best practices in rare disease transition [11].

Mental Health and Adherence Considerations

Adolescents transitioning out of pediatric care for any chronic therapy show adherence drops of 20 to 50% in the first 12 months [12]. NMN and NR require daily dosing to maintain elevated blood NAD+. Blood NAD+ returns to baseline within roughly 24 to 48 hours of stopping oral NR, based on the washout kinetics in Trammell et al. [4]. Discussing this pharmacokinetic reality with the adolescent patient directly, in age-appropriate language, before the transition is complete improves adherence more reliably than written reminders alone.

Evidence Gaps and Research Priorities

The absence of pediatric trial data is the defining clinical challenge in this area.

No Pediatric PK Data

No published study has measured plasma NMN, NR, or their metabolites (NAAD, NAMN, MeNAM) after oral administration in children under 12. Without pediatric pharmacokinetic data, dose selection remains entirely empirical.

No Long-Term Safety Data in Children

The longest adult NR safety study is 12 weeks at 2,000 mg/day (Dellinger et al., Nature Aging 2021, N=30 older adults) [13]. There are no 12-week, let alone 12-month, safety datasets in children. Bone mineral density, growth velocity, and pubertal progression are outcomes that would need monitoring in any future pediatric trial.

The ClinicalTrials.gov Field

A search of ClinicalTrials.gov as of mid-2025 returns zero registered trials of NMN or NR in participants under 18. The FDA Pediatric Research Equity Act (PREA) does not apply to dietary supplements, meaning there is no regulatory mechanism compelling sponsors to generate pediatric data [14]. Families and clinicians are therefore operating without the safety net that PREA provides for pediatric drug development.

What Clinicians Should Tell Families Right Now

Families asking about NMN or NR for a child under 12 deserve direct, evidence-grounded answers rather than reflexive dismissal or uncritical enthusiasm.

For Healthy Children With No Metabolic Diagnosis

There is no evidence supporting NMN or NR supplementation in healthy children under 12. Basal NAD+ levels are high in this age group, the biological rationale for supplementation is absent, and regulatory concerns around NMN specifically add another layer of caution. The recommendation is not to use either compound in healthy children under 12.

For Children With a Diagnosed NAD+ Metabolism Disorder

Use is appropriate only under the direct supervision of a pediatric metabolic specialist, with documented indication, baseline labs, and a transition plan in place by age 10. Niacin remains the first-line repletion agent with the most established pediatric safety record. NR may be considered when niacin is not tolerated, but this should be documented as off-label use.

The Consent and Assent Framework

Children aged 7 and older are generally capable of meaningful assent to ongoing treatment under American Academy of Pediatrics guidance [15]. Any child over 7 currently on NMN or NR should be included in the conversation about their therapy at each review visit. By age 14, the patient's own understanding of their condition and treatment should be assessed formally as part of the transition readiness evaluation.

Formulation Considerations Relevant to Pediatric Patients

Capsule-based NR and NMN products are the dominant commercial forms. Most pediatric patients under 12 cannot swallow a 500 mg capsule reliably. Practical considerations include:

• Powder-form NR that can be dissolved in water or juice. NR has a slightly bitter taste; mixing with juice improves palatability.
• NMN powder is similarly available but carries the FDA regulatory concern noted above.
• Sublingual NMN formulations claim faster absorption; no pediatric data supports or refutes this claim, and adult bioavailability comparisons between sublingual and oral NMN are not yet published in peer-reviewed form.
• Compounded formulations from 503A pharmacies can be prepared in child-appropriate doses and flavored vehicles, though the stability of NMN and NR in aqueous suspension at room temperature has not been formally studied.

Regardless of formulation, storage away from heat and light is recommended because both NMN and NR are susceptible to oxidative degradation, a concern relevant to any household with small children where a caregiver is managing medication preparation.